ABSTRACT Chronic rhinosinusitis (CRS), a complex inflammatory disease with heterogeneous pathogenesis, demands evolving evidence‐based strategies. Since the 2018 Chinese guidelines and EPOS2020, international advances in CRS immunopathology and biologics have revolutionized therapeutic approaches, particularly through phenotype–endotype classification and targeted therapies. Concurrently, Chinese research has achieved globally competitive milestones, including phenotype–endotype‐driven mechanistic studies, biomarker discovery, and high‐quality RCTs evaluating biologics, significantly advancing precision management algorithms. This 2024 update rigorously incorporates China‐specific evidence from systematic literature reviews and multicenter studies. Key revisions address critical clinical challenges through structured expert consensus. Newly added evidence tiers and clinical decision pathways enhance practicality for diverse healthcare settings. By integrating domestic innovations with global standards, this guideline establishes a pragmatic framework for personalized care while prioritizing real‐world applicability, ultimately aiming to standardize CRS management in China's evolving clinical landscape.
Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery Subspecialty Group of Rhinology (Thu,) studied this question.